

# Zopa Retreatment and Vector Shedding in Adults With RRP

NCT06538480

---

Status	RECRUITING
Phase	Phase 4
Sponsor	Precigen, Inc
Enrollment	30 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Age 18 years and older.
- Clinical diagnosis of recurrent respiratory papillomatosis with histological confirmation of papilloma.
- Cohort 1: Treatment-naïve with respect to Zopa.
- Cohort 2: Received a minimum of four administrations of Zopa at  $5 \times 10^{11}$  PU per injection and require clinically indicated debulking procedures.
- Presence of laryngotracheal papillomas accessible for endoscopic cleanout.

... and 3 more (see full listing online)

### Exclusion (7)

- Conditions or therapies that increase risk or interfere with participation per investigator judgment.
- Systemic corticosteroids  $>10$  mg prednisone equivalent or other immunosuppressive medications within 14 days prior to dosing.
- Other systemic RRP treatments or investigational agents within 30 days.
- History of heparin-induced thrombocytopenia or vaccine-induced thrombotic thrombocytopenia.
- Active uncontrolled HIV, hepatitis B, or hepatitis C infection.

... and 2 more (see full listing online)

## Locations (3 total)

---

Winship Cancer Institute, Emory University, Atlanta, Georgia, United States  
National Institute of Health, Bethesda, Maryland, United States  
University of Cincinnati, Cincinnati, Ohio, United States